General
Preferred name
PACLITAXEL
Synonyms
BMS-181339-01 ()
Taxol ()
CHEMBL428647 ()
NSC 125973 ()
Paclitaxel (Taxol) ()
7 epi Taxol ()
7-epi-Taxol ()
Bris Taxol ()
NSC125973 ()
Praxel ()
Anzatax ()
Taxol (Registered Trademark) ()
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv. ()
Benzenepropanoic acid, .beta.-(benzoylamino)- .alpha.-hydroxy-, 6,12b-bis(acetyl oxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b,- dodecahydro-4,11- dihydroxy-4a,8,13,13-tetramethyl-5-oxo- 7,11-methano- 1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR- [2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(alpha. R*,.beta.S*),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]- ()
Tax-11-en-9-one, 5.beta.,20-epoxy-1,2.alpha.,4,7.beta., 10.beta.,13.alpha.- hexahydroxy-, 4,10-diacetate 2- benzoate,13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine ()
paclitaxel, Shanghai Fudan-Zhangjiang ()
ABI-007 COMPONENT PACLITAXEL ()
BMS 181339-01 ()
(-)-paclitaxel ()
Lep-etu ()
Onxol ()
Taxalbin ()
MBT-0206 ()
PACLITAXOL ()
Taxus liberte ()
Genexol-pm ()
Intaxel ()
Paxene ()
Genaxol ()
MBT 0206 ()
Endotag 1 ()
Yewtaxan ()
Pacliex ()
NSC-125973 ()
Pacitaxel ()
Empac ()
Plaxicel ()
Taxol 100 ()
Taxus stent ()
NK-105 ()
DHP 107 ()
Taxus ()
Taxol A ()
Abraxane ()
Onxal ()
NK 105 ()
Genetaxyl ()
DHP-107 ()
Capxol ()
Paclitaxel (taxus canadensis) ()
Ebetaxel ()
Genexol ()
ABI-007 ()
Mitotax ()
Tocosol paclitaxel ()
QW-8184 ()
Oncogel ()
Cyclopax ()
Paclitaxel-d5 ()
P&D ID
PD004086
CAS
33069-62-4
1203669-79-7
1129540-33-5
Tags
nuisance
natural product
probe
drug
available
Approved by
PMDA
EMA
FDA
First approval
1992
Drug Status
withdrawn
approved
vet_approved
Drug indication
Ovarian cancer
Antineoplastic
Pancreatic cancer
Gastric adenocarcinoma
Breast cancer
Solid tumour/cancer
Max Phase
Phase 4
Probe info
Probe type
calculated probe
experimental probe
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Paclitaxel is a tubulin inhibitor. It was originally identified and isolated from the bark of the Pacific yew, Taxus brevifolia (hence the name 'taxol', and naming of the taxane family of compounds- includes and ). The drug can be administered as a solvent-based drug, or in a formulation called nab-paclitaxel. Nab-paclitaxel consists of paclitaxel bound to albumin nanoparticles as a delivery vehicle (trade name Abraxane)- nab stands for nanoparticle albumin-bound. (GtoPdb)
MOA Stabilizes nonfunctional microtubules
MOA Inhibitor (Chemical Probes.org)
Cell lines
575
Organisms
5
Compound Sets
35
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Chemical Probes.org
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
High-quality chemical probes
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
Nuisance compounds in cellular assays
Prestwick Chemical Library
Reference compounds for characterizing cellular injury in high-content cellular morphology assays
ReFrame library
TargetMol Bioactive Compound Library
Tool Compound Set
Welcome Trust Cancer Drugs
Withdrawn 2.0
External IDs
69
Properties
(calculated by RDKit )
Molecular Weight
853.33
Hydrogen Bond Acceptors
14
Hydrogen Bond Donors
4
Rotatable Bonds
10
Ring Count
7
Aromatic Ring Count
3
cLogP
3.74
TPSA
221.29
Fraction CSP3
0.45
Chiral centers
11.0
Largest ring
8.0
QED
0.13
Structural alerts
1
Tubulin modulation
Nuisance compounds in cellular assays
Custom attributes
(extracted from source data)
Target
Tubulin beta-3 chain
Beta subunit of Tubulin
Microtubule
BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8
Beta-Tubulin
ADC Cytotoxin
Microtubule/Tubulin
TUBB
Pathway
cytoskeleton
Cytoskeletal Signaling
Antibody-drug Conjugate/ADC Related
Apoptosis
Autophagy
Cell Cycle/DNA Damage
Member status
member
MOA
Microtubule stabilizer
tubulin polymerization inhibitor
Indication
ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)
Cellular injury category
Cytoskeletal
ATC
L01CD01
Target subclass
Cytoskeleton
GTPase
Target class
Structural protein
Enzyme
Therapeutic Class
Anticancer Agents
Source data